Article

Risk of fracture with thiazolidinediones: disease or drugs?

Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Calcified Tissue International (Impact Factor: 2.75). 04/2012; 90(6):450-7. DOI: 10.1007/s00223-012-9591-8
Source: PubMed

ABSTRACT The use of thiazolidinediones (TZDs) has been associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) has been linked with fracture. We evaluated to what extent the association between TZD use and fracture risk is related to the drug or to the underlying disease. We conducted a population-based cohort study using the Danish National Health Registers (1996-2007), which link pharmacy data to the national hospital registry. Oral antidiabetic users (n = 180,049) were matched 1:3 by year of birth and sex to nonusers. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture. Time-dependent adjustments were made for age, comorbidity, and drug use. We created a proxy indicator for the severity of disease. The first stage was defined as current use of either a biguanide or a sulfonyluerum, the second stage as current use of a biguanide and a sulfonyluerum at the same time, the third stage as patients using TZDs, and the fourth stage as patients using insulin. The risk of osteoporotic fracture was increased 1.3-fold for stages 3 and 4 compared with controls. Risk with current TZD use (stage 3 HR = 1.27, 95 % CI 1.06-1.52) and risk with current use of insulin (stage 4 HR = 1.25, 95 % CI 1.20-1.31) were similar. In the first (HR = 1.15, 95 % CI 1.13-1.18) and second (HR = 1.00, 95 % CI 0.96-1.04) stages risks were lower. Risk of osteoporotic fracture was similar for TZD users and insulin users. When studying fracture risk with TZDs, the underlying T2DM should be taken into account.

0 Bookmarks
 · 
160 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to compare contemporary risk of hip fracture in type 1 and type 2 diabetes with the non-diabetic population. Using a national diabetes database, we identified those with type 1 and type 2 diabetes aged 20-84 years alive anytime from 01/01/2005 to 12/31/2007. All hospitalised events for hip fracture in 2005-2007 for diabetes patients were linked and compared to general population counts. Age- and calendar- year-adjusted Incidence Rate Ratios (IRR) were calculated by diabetes type and sex. One hundred and five hip fractures occurred in 21,033 people (59,585 person-years) with type 1 diabetes; 1,421 in 180,841 people (462,120 person-years) with type 2 diabetes and 11,733 hip fractures over 10,980,599 person-years in the non-diabetic population (3.66 million people). Those with Type 1 diabetes had substantially elevated risks of hip fracture compared to the general population Incidence risk ratio (IRR)3.28 [95% Confidence Interval: 2.52-4.26] in men and 3.54 [2.75-4.57] in women. The IRR was greater at younger ages but absolute risk difference was greatest at older ages. In type 2 diabetes, there was no elevation in risk among men (IRR 0.97 [0.92-1.02]) and the increase in risk in women was small (1.05 [1.01-1.10]). There remains a substantial elevation relative risk of hip fracture in people with type 1 diabetes but the relative risk is much lower than in earlier studies. In contrast overall there is currently little elevation in overall hip fracture risk with type 2 diabetes but this may mask elevations in risk in particular subgroups of type 2 diabetes patients with different BMI or diabetes duration or drug exposure. © 2013 American Society for Bone and Mineral Research.
    Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 10/2013; · 6.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context:Meta-analyses of clinical studies have suggested an increased incidence of peripheral fractures in postmenopausal women with type 2 diabetes mellitus taking pioglitazone. The mechanism behind this apparent increase is unknown.Objective:The objective of the study was to examine the effects of pioglitazone on bone mineral density (BMD) and turnover.Design and Setting:Twenty-five sites (in the United States) enrolled participants in this randomized, double-blind, placebo-controlled study.Participants:Postmenopausal women (n = 156) with impaired fasting glucose or impaired glucose tolerance participated in the study.Interventions:The intervention consisted of pioglitazone 30 mg/d (n = 78) or placebo (n = 78), increased to 45 mg/d after 1 month, for 12 months of treatment total, followed by 6 months of washout/follow-up.Main Outcome Measures:Percentage changes from baseline to month 12 and from month 12 to month18 in BMD in total proximal femur (primary end point), total body, femoral neck, lumbar spine, and radius were measured.Results:Least squares mean changes from baseline to month 12 in total proximal femur BMD were -0.69% for pioglitazone and -0.14% for placebo (P = .170). No statistically significant between-group differences were observed for any BMD or bone remodeling marker end point. We observed improved glycemic control and insulin sensitivity with pioglitazone treatment. In addition, pioglitazone appeared to increase body fat, which may affect bone density measurements, especially in the lumbar spine. One pioglitazone-treated and three placebo-treated women experienced confirmed fractures. Over 18 months, one pioglitazone-treated (1.3%) and eight placebo-treated women (10.3%) developed overt type 2 diabetes mellitus. The pattern and incidence of adverse events with pioglitazone were consistent with clinical experience with thiazolidinediones.Conclusions:Maximal-dose pioglitazone had no effects on BMD or bone turnover, while improving glycemic control as expected, in postmenopausal women with impaired fasting glucose or impaired glucose tolerance.
    The Journal of Clinical Endocrinology and Metabolism 09/2013; · 6.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since their approval, thiazolidinediones (TZDs) have been used extensively as insulin-sensitizers for the management of type 2 diabetes mellitus (T2DM). Activation of peroxisomal proliferator-activated receptor gamma (PPARγ) nuclear receptors by TZDs leads to a vast spectrum of metabolic and antiinflammatory effects. In the past decade, clinicians and scientists across the fields of metabolism, diabetes, liver disease (NAFLD), atherosclerosis, inflammation, infertility, and even cancer have had high hopes about the potential for TZDs to treat many of these diseases. However, an increasing awareness about undesirable "off-target" effects of TZDs have made us rethink their role and be more cautious about the long-term benefits and risks related to their use. This review examines the most relevant work on the benefits and risks associated with TZD treatment, with a focus on the only PPARγ agonist currently available (pioglitazone), aiming to offer the reader a balanced overview about the current and future role of TZDs in the management of insulin-resistant states and T2DM.
    Current Diabetes Reports 04/2013; · 3.38 Impact Factor

Full-text (2 Sources)

Download
72 Downloads
Available from
May 30, 2014